Medicine
Cerianna 100 mCi/mL injection
Cerianna 100 mCi/mL injection is a prescription medicine containing Fluoroestradiol f-18 for intravenous use, marketed by GE Healthcare, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store CERIANNA at controlled room temperature (USP) 20°C to 25°C (68°F to…
Key facts
- Active ingredient (INN)
- Fluoroestradiol f-18
- Brand
- Cerianna
- Strength
- 100 mCi/mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 50 mL
- Marketing authorisation holder
- GE Healthcare
- Manufacturer
- GE Healthcare
- Origin register
- US FDA, United States
- Storage
- Store CERIANNA at controlled room temperature (USP) 20°C to 25°C (68°F to 77°F). Store CERIANNA upright in the original container with radiation shielding.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V09IX11 Fluoroestradiol f-18
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 May 2020
- Identifiers
- DailyMed set ID b2c2a2df-cf3e-4a29-a033-231ed5a94b58NDC 72874-001Application NDA212155
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 50 mL in 1 vial, multi-dose | 72874-001-01 | GE Healthcare | 20 May 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 20 May 2020 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Fluoroestradiol f-18 is a radioactive diagnostic agent indicated with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. MedsAcross supplies Fluoroestradiol f-18 for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Fluoroestradiol f-18For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- CERIANNA prescribing information (GE Healthcare) · U.S. National Library of Medicine, DailyMed
Need Cerianna 100 mCi/mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.